RANKL: Osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis

Arthritis and Rheumatism

Volumn 56, Issue 3, 2007, Pages 977-983

  Rouster Stevens, Kelly A ^a   Langman, Craig B ^a   Price, Heather E ^a   Seshadri, Roopa ^a   Shore, Richard M ^a   Abbott, Kathy ^a   Pachman, Lauren M ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Box 212 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ARTICLE; BONE DENSITY; BONE METABOLISM; CELL FUNCTION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE DURATION; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; HUMAN; JUVENILE DERMATOMYOSITIS; LUMBAR SPINE; MALE; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RASH; SERUM; STATISTICAL ANALYSIS; UNITED STATES; WEAKNESS;

BONE DENSITY; BONE RESORPTION; CASE-CONTROL STUDIES; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; DENSITOMETRY, X-RAY; DERMATOMYOSITIS; FEMALE; HUMANS; INFANT; MALE; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND;

EID: 33947108436     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22433     Document Type: Article

References (30)

1. Reed A, Haugen M, Pachman LM, Langman CB. Repair of osteopenia in children with juvenile rheumatoid arthritis. J Pediatr 1993;122(5 Pt 1):693-6.
2. Henderson CJ, Cawkwell GD, Specker BL, Sierra RI, Wilmott RW, Campaigne BN, et al. Predictors of total bone mineral density in non-corticosteroid- treated prepubertal children with juvenile rheumatoid arthritis. Arthritis Rheum 1997;40:1967-75.
3. Brik R, Keidar Z, Schapira D, Israel O. Bone mineral density and turnover in children with systemic juvenile chronic arthritis. J Rheumatol 1998;25:990-2.
4. Cetin A, Celiker R, Dincer F, Ariyurek M. Bone mineral density in children with juvenile chronic arthritis. Clin Rheumatol 1998; 17:551-3.
5. Polito C, Strano CG, Rea L, Alessio M, Iammarrone CS, Todisco N, et al. Reduced bone mineral content and normal serum osteocalcin in non-steroid-treated patients with juvenile rheumatoid arthritis. Ann Rheum Dis 1995;54:193-6.
6. Lien G, Selvaag AM, Flato B, Haugen M, Vinje O, Sorskaar D, et al. A two-year prospective controlled study of bone mass and bone turnover in children with early juvenile idiopathic arthritis. Arthritis Rheum 2005;52:833-40.
7. Mendez EP, Lipton R, Dyer A, Ramsey-Goldman R, Roettcher P, Bowyer S, et al, for the NIAMS Juvenile DM Registry Physician Referral Group. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003;49:300-5.
8. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts) [review]. N Engl J Med 1975;292:344-7.
9. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts) [review]. N Engl J Med 1975;292:403-7.
10. Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 2003;49: 7-15.
11. Pachman LM. Duration of illness is an important variable for children with untreated juvenile dermatomyositis. J Pediatr 2006; 148:247-53.
12. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175-9.
13. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999;96:3540-5.
14. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Goto M, et al. A novel molecular mechanism modulating osteoclast differentiation and function. Bone 1999;25:109-13.
15. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.
16. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki SI, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL Proc Natl Acad Sci 1998;95: 3597-602.
17. Quinn JW, Elliott J, Gillespie MT, Martin TJ. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998;139:4424-7.
18. Matsuzaki K, Udagawa N, Takahashi N, Yamaguchi K, Tasuda H, Shima N, et al. Osteoclast differentiation factor induces osteoclastlike cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Com 1998;246:199-204.
19. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998;188:997-1001.
20. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
21. Yasuda H, Shima N, Murakami A, Tsuda E, Morinaga T, Higashio K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998;38:1329-37.
22. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2-12.
23. Wacker W, Barden HS. Pediatric reference data for male and female total body and spine BMD and BMC [abstract]. International Society of Clinical Densitometry. Dallas, TX. March, 2001.
24. Varsani H, Patel A, van Kooyk Y, Woo P, Wedderburn LR. Synovial dendritic cells in juvenile idiopathic arthritis (JIA) express receptor activator of NF-kB (RANK). Rheumatology 2003; 42:583-90.
25. Masi L, Simonini G, Piscitelli E, Del Monte F, Giani T, Cimaz R, et al. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/ RANK-L in bone injury? J Rheum 2004;31:986-91.
26. Stewart WA, Acott PD, Salisbury SR, Lang BA. Bone mineral density in juvenile dermatomyositis: assessment using dual x-ray absorptiometry. Arthritis Rheum 2003;48:2294-8.
27. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, et al, for the Study of Osteoporotic Fractures Research Group. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:972-5.
28. Elsasser U, Wilkins B, Hesp R, Thurnham DI, Reeve J, Ansell BM. Bone rarefaction and crush fractures in juvenile chronic arthritis. Arch Dis Child 1982;57:377-80.
29. Varonos S, Ansell BM, Reeve J. Vertebral collapse in juvenile chronic arthritis: its relationship with glucocorticoid therapy. Calcif Tissue Int 1987;42:75-8.
30. Murray KJ, Boyle RJ, Woo P. Pathological fractures and osteoporosis in a cohort of 103 systemic onset juvenile idiopathic arthritis patients [abstract]. Arthritis Rheum 2000;43:S119.